Oncogenic intra-p53 family member interactions in human cancers

Frontiers in Oncology

Volumn 6, Issue MAR, 2016, Pages

  Ferraiuolo, Maria ^a   Di Agostino, Silvia ^a   Blandino, Giovanni ^a   Strano, Sabrina ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Differentiation; Gain of function; Homology; Isoforms; P53 gene family members; Protein protein interaction; Target genes

Indexed keywords

CISPLATIN; ETOPOSIDE; PROTEIN P53; PROTEIN P63; PROTEIN P73;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL INVASION; DNA DAMAGE; HUMAN; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY;

EID: 84964469250     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00077     Document Type: Short Survey

References (184)

1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 2:305-16. doi:10.1016/S1097-2765(00)80275-0
2. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature (1999) 398:714-8. doi:10.1038/19539
3. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 18:90-5. doi:10.1016/S0168-9525(02)02595-7
4. Bergholz J, Xiao ZX. Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron (2012) 5:311-22. doi:10.1007/s12307-012-0116-9
5. Kaelin WG Jr. Another p53 Doppelganger? Science (1998) 281:57-8
6. Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst (1999) 91:594-8. doi:10.1093/jnci/91.7.594
7. Kaelin WG Jr. The p53 gene family. Oncogene (1999) 18:7701-5. doi:10.1038/sj.onc.1202955
8. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (2000) 404:99-103. doi:10.1038/35003607
9. Monti O, Damalas A, Strano S, Blandino G. p73, p63 and mutant p53: members of protein complexes floating in cancer cells. 2007 ed. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer (2007). p. 223-32
10. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 28:663-70. doi:10.1016/j.tibs.2003.10.004
11. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci (2004) 61:822-42. doi:10.1007/s00018-003-3304-4
12. Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J (2005) 389:443-55. doi:10.1042/BJ20041980
13. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ (2010) 17:901-11. doi:10.1038/cdd.2010.35
14. Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem Sci (2015) 40:425-34. doi:10.1016/j.tibs.2015.04.007
15. Lin J, Teresky AK, Levine AJ. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene (1995) 10:2387-90
16. Sauer M, Bretz AC, Beinoraviciute-Kellner R, Beitzinger M, Burek C, Rosenwald A, et al. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Nucleic Acids Res (2008) 36:1900-12. doi:10.1093/nar/gkn044
17. Lane DP. Cancer. p53, guardian of the genome. Nature (1992) 358:15-6. doi:10.1038/358015a0
18. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, et al. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 134:193-204. doi:10.1083/jcb.134.1.193
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell (1997) 88:323-31. doi:10.1016/S0092-8674(00)81871-1
20. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev (1998) 12:2973-83. doi:10.1101/gad.12.19.2973
21. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 19:1751-8. doi:10.1128/MCB.19.3.1751
22. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem (1999) 274:36031-4. doi:10.1074/jbc.274.51.36031
23. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature (2000) 408:307-10. doi:10.1038/35042675
24. Vousden KH. p53: death star. Cell (2000) 103:691-4. doi:10.1016/S0092-8674(00)00171-9
25. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 6:909-23. doi:10.1038/nrc2012
26. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell (2006) 24:593-602. doi:10.1016/j.molcel.2006.10.018
27. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 9:702-12. doi:10.1038/nrm2451
28. Kruse JP, Gu W. Modes of p53 regulation. Cell (2009) 137:609-22. doi:10.1016/j.cell.2009.04.050
29. Kress M, May E, Cassingena R, May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol (1979) 31:472-83
30. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 278:261-3. doi:10.1038/278261a0
31. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 17:43-52. doi:10.1016/0092-8674(79)90293-9
32. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell (2009) 137:413-31. doi:10.1016/j.cell.2009.04.037
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 54:4855-78
34. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res (1997) 25:151-7. doi:10.1093/nar/25.1.151
35. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 9:701-13. doi:10.1038/nrc2693
36. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev (2012) 26:1268-86. doi:10.1101/gad.190678.112
37. Prives C, Hall PA. The p53 pathway. J Pathol (1999) 187:112-26. doi:10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.3.CO;2-V
38. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A (1999) 96:8438-42. doi:10.1073/pnas.96.15.8438
39. Chan WM, Siu WY, Lau A, Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol (2004) 24:3536-51. doi:10.1128/MCB.24.8.3536-3551.2004
40. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res (2007) 97:1-23. doi:10.1016/S0065-230X(06)97001-8
41. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem (2005) 280:43100-8. doi:10.1074/jbc. M505590200
42. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 18:477-85. doi:10.1038/sj.onc.1202314
43. Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J (2000) 14:2291-302. doi:10.1096/fj.00-0128com
44. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 60:6788-93
45. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 20:4163-72. doi:10.1093/emboj/20.15.4163
46. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 277:18817-26. doi:10.1074/jbc. M201405200
47. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 10:191-202. doi:10.1016/j.ccr.2006.08.013
48. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene (2007) 26:2220-5. doi:10.1038/sj.onc.1210311
49. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 12:303-12. doi:10.1016/j.ccr.2007.10.001
50. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene (2007) 26:2212-9. doi:10.1038/sj.onc.1210296
51. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 67:2396-401. doi:10.1158/0008-5472.CAN-06-2425
52. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene (2007) 26:2202-11. doi:10.1038/sj.onc.1210294
53. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 16:1086-93. doi:10.1038/nsmb.1669
54. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 139:1327-41. doi:10.1016/j.cell.2009.11.026
55. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 2:a001107. doi:10.1101/cshperspect.a001107
56. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 17:273-85. doi:10.1016/j.ccr.2009.11.025
57. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene (2014) 33:1601-8. doi:10.1038/onc.2013.106
58. Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, et al. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget (2015) 6:5547-66. doi:10.18632/oncotarget.2587
59. Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene (1997) 15:1363-7. doi:10.1038/sj.onc.1201500
60. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer (2002) 2:605-15. doi:10.1038/nrc861
61. Cancino GI, Miller FD, Kaplan DR. p73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer's disease. Neurobiol Aging (2013) 34:387-99. doi:10.1016/j.neurobiolaging.2012.04.010
62. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, et al. Activation of p73 silent allele in lung cancer. Cancer Res (1998) 58:2347-9
63. Irwin MS, Kaelin WG Jr. Role of the newer p53 family proteins in malignancy. Apoptosis (2001) 6:17-29. doi:10.1023/A:1009663809458
64. Bantel H, Simon HU. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle (2010) 9:2710-1. doi:10.4161/cc.9.14.12592
65. Casciano I, Ponzoni M, Lo Cunsolo C, Tonini GP, Romani M. Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma. Cell Death Differ (1999) 6:391-3. doi:10.1038/sj.cdd.4400522
66. Carastro LM, Lin HY, Park HY, Kim D, Radlein S, Hampton KK, et al. Role of p73 dinucleotide polymorphism in prostate cancer and p73 protein isoform balance. Prostate Cancer (2014) 2014:129582. doi:10.1155/2014/129582
67. Lee KE, Hong YS, Kim BG, Kim NY, Lee KM, Kwak JY, et al. p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol (2010) 16:4448-54. doi:10.3748/wjg.v16.i35.4448
68. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (1995) 377:646-9. doi:10.1038/377646a0
69. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 80:293-9. doi:10.1016/0092-8674(95)90412-3
70. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 389:191-4. doi:10.1038/38298
71. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 90:809-19. doi:10.1016/S0092-8674(00)80540-1
72. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res (1998) 58:5061-5
73. Okamoto K, Prives C. A role of cyclin G in the process of apoptosis. Oncogene (1999) 18:4606-15. doi:10.1038/sj.onc.1202821
74. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res (1999) 59:3257-63
75. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol (2001) 21:8461-70. doi:10.1128/MCB.21.24.8461-8470.2001
76. Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 277:43359-68. doi:10.1074/jbc. M205573200
77. Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A, et al. From p63 to p53 across p73. FEBS Lett (2001) 490:163-70. doi:10.1016/S0014-5793(01)02119-6
78. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 276:15164-73. doi:10.1074/jbc. M010484200
79. Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, et al. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene (2006) 25:3628-37. doi:10.1038/sj.onc.1209401
80. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 101:4401-6. doi:10.1073/pnas.0400805101
81. Lin D, Cui Z, Kong L, Cheng F, Xu J, Lan F. p73 participates in WWOX-mediated apoptosis in leukemia cells. Int J Mol Med (2013) 31:849-54. doi:10.3892/ijmm.2013.1289
82. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 399:809-13. doi:10.1038/21697
83. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 399:806-9. doi:10.1038/21690
84. White E, Prives C. DNA damage enables p73. Nature (1999) 399(734-735):737. doi:10.1038/21544
85. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 399:814-7. doi:10.1038/21704
86. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 9:175-86. doi:10.1016/S1097-2765(02)00431-8
87. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell (2005) 18:447-59. doi:10.1016/j.molcel.2005.04.008
88. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 20:599-606. doi:10.1038/nm.3562
89. Senoo M, Seki N, Ohira M, Sugano S, Watanabe M, Inuzuka S, et al. A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun (1998) 248:603-7. doi:10.1006/bbrc.1998.9013
90. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med (1998) 4:747-8. doi:10.1038/nm0798-747
91. Dohn M, Zhang S, Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene (2001) 20:3193-205. doi:10.1038/sj.onc.1204427
92. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol (2006) 8:551-61. doi:10.1038/ncb1420
93. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 20:1028-42. doi:10.1101/gad.1406006
94. Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, et al. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY) (2016) 8(2):345-65
95. Vanbokhoven H, Melino G, Candi E, Declercq W. p63, a story of mice and men. J Invest Dermatol (2011) 131:1196-207. doi:10.1038/jid.2011.84
96. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 7:363-73. doi:10.1016/j.ccr.2005.02.019
97. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM, et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A (2006) 103:8435-40. doi:10.1073/pnas.0602477103
98. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer (2013) 13:136-43. doi:10.1038/nrc3446
99. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell (2003) 11:11-23. doi:10.1016/S1097-2765(02)00776-1
100. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 32:803-14. doi:10.1016/j.molcel.2008.11.019
101. Xiao Q, Qian Z, Zhang W, Liu J, Hu E, Zhang J, et al. Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation. Oncotarget (2016). doi:10.18632/oncotarget.7069
102. Blandino G, Dobbelstein M. p73 and p63: why do we still need them? Cell Cycle (2004) 3:886-94. doi:10.4161/cc.3.7.996
103. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 265:346-55. doi:10.1126/science.8023157
104. De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci (2000) 926:90-100. doi:10.1111/j.1749-6632.2000.tb05602.x
105. Marin MC, Kaelin WG Jr. p63 and p73: old members of a new family. Biochim Biophys Acta (2000) 1470:M93-100
106. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 13:962-72. doi:10.1038/sj.cdd.4401914
107. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 22:8601-11. doi:10.1128/MCB.22.24.8601-8611.2002
108. Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol (2010) 2:a000927. doi:10.1101/cshperspect.a000927
109. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med (1998) 188:1763-8. doi:10.1084/jem.188.9.1763
110. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ (1999) 6:389-90. doi:10.1038/sj.cdd.4400521
111. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science (2000) 289:304-6. doi:10.1126/science.289.5477.304
112. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, et al. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene (2001) 20:514-22. doi:10.1038/sj.onc.1204118
113. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res (2002) 62:636-41
114. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem (2002) 277:14177-85. doi:10.1074/jbc. M200480200
115. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res (2002) 62:3598-602
116. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 19:2122-37. doi:10.1101/gad.1339905
117. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res (2009) 37:6092-104. doi:10.1093/nar/gkp674
118. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol (2000) 1:199-207. doi:10.1038/35044563
119. Senoo M, Matsumura Y, Habu S. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene (2002) 21:2455-65. doi:10.1038/sj.onc.1205330
120. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell (2006) 9:45-56. doi:10.1016/j.ccr.2005.12.013
121. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene (2007) 26:5169-83. doi:10.1038/sj.onc.1210337
122. Bisso A, Collavin L, Del Sal G. p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 17:578-90. doi:10.2174/138161211795222667
123. Memmi EM, Sanarico AG, Giacobbe A, Peschiaroli A, Frezza V, Cicalese A, et al. p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A (2015) 112:3499-504. doi:10.1073/pnas.1500762112
124. Orzol P, Nekulova M, Holcakova J, Muller P, Votesek B, Coates PJ. DeltaNp63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer. Tumour Biol (2016). doi:10.1007/s13277-016-4880-x
125. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 19:1438-49. doi:10.1128/MCB.19.2.1438
126. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 25:47-54. doi:10.1038/75586
127. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 275:29503-12. doi:10.1074/jbc. M003360200
128. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 3:387-402. doi:10.1016/S1535-6108(03)00079-5
129. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet (2003) 33:357-65. doi:10.1038/ng1093
130. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol (2001) 21:1874-87. doi:10.1128/MCB.21.5.1874-1887.2001
131. Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, et al. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem (2003) 278:10546-55. doi:10.1074/jbc. M208233200
132. Hinds PW, Finlay CA, Frey AB, Levine AJ. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol (1987) 7:2863-9. doi:10.1128/MCB.7.8.2863
133. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet (1993) 4:42-6. doi:10.1038/ng0593-42
134. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 18:3735-43. doi:10.1128/MCB.18.7.3735
135. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A (1998) 95:5166-71. doi:10.1073/pnas.95.9.5166
136. Santini S, Di Agostino S, Coppari E, Bizzarri AR, Blandino G, Cannistraro S. Interaction of mutant p53 with p73: a surface plasmon resonance and atomic force spectroscopy study. Biochim Biophys Acta (2014) 1840:1958-64. doi:10.1016/j.bbagen.2014.02.014
137. Bizzarri AR, Cannistraro S. Atomic force spectroscopy in biological complex formation: strategies and perspectives. J Phys Chem B (2009) 113:16449-64. doi:10.1021/jp902421r
138. Bizzarri AR, Cannistraro S. The application of atomic force spectroscopy to the study of biological complexes undergoing a biorecognition process. Chem Soc Rev (2010) 39:734-49. doi:10.1039/b811426a
139. Cooper MA. Label-free screening of bio-molecular interactions. Anal Bioanal Chem (2003) 377:834-42. doi:10.1007/s00216-003-2111-y
140. Homola J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem Rev (2008) 108:462-93. doi:10.1021/cr068107d
141. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell (2014) 157:382-94. doi:10.1016/j.cell.2014.01.066
142. Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol (2011) 31:4464-81. doi:10.1128/MCB.05574-11
143. Wang G, Fersht AR. Propagation of aggregated p53: cross-reaction and coaggregation vs. seeding. Proc Natl Acad Sci U S A (2015) 112:2443-8. doi:10.1073/pnas.1500262112
144. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH. Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene (2015) 34:4300-10. doi:10.1038/onc.2014.359
145. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 356:215-21. doi:10.1038/356215a0
146. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell (1999) 99:143-53. doi:10.1016/S0092-8674(00)81646-3
147. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature (1999) 398:708-13. doi:10.1038/19531
148. van Bokhoven H, Brunner HG. Splitting p63. Am J Hum Genet (2002) 71:1-13. doi:10.1086/341450
149. Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T, et al. RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle (2004) 3:1285-95. doi:10.4161/cc.3.10.1155
150. Zangen R, Ratovitski E, Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle (2005) 4:1313-5. doi:10.4161/cc.4.10.2066
151. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem (1999) 274:18709-14. doi:10.1074/jbc.274.26.18709
152. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res (2006) 66:9362-8. doi:10.1158/0008-5472.CAN-06-1619
153. Di C, Sun C, Li H, Si J, Zhang H, Han L, et al. Diallyl disulfide enhances carbon ion beams-induced apoptotic cell death in cervical cancer cells through regulating Tap73/DeltaNp73. Cell Cycle (2015) 14:3725-33. doi:10.1080/15384101.2015.1104438
154. Gonfloni S, Caputo V, Iannizzotto V. P63 in health and cancer. Int J Dev Biol (2015) 59:87-93. doi:10.1387/ijdb.150045sg
155. Lucena-Araujo AR, Kim HT, Thome C, Jacomo RH, Melo RA, Bittencourt R, et al. High DeltaNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood (2015) 126:2302-6. doi:10.1182/blood-2015-01-623330
156. Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, et al. Mutant p53 proteins: between loss and gain of function. Head Neck (2007) 29:488-96. doi:10.1002/hed.20531
157. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol (2011) 2011:978312. doi:10.1155/2011/978312
158. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol (2012) 2012:170325. doi:10.1155/2012/170325
159. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 25:304-17. doi:10.1016/j.ccr.2014.01.021
160. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. Chemosensitivity linked to p73 function. Cancer Cell (2003) 3:403-10. doi:10.1016/S1535-6108(03)00078-3
161. Strano S, Blandino G. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle (2003) 2:348-9. doi:10.4161/cc.2.4.426
162. Irwin MS. Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle (2004) 3:319-23. doi:10.4161/cc.3.3.768
163. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 7:683-94. doi:10.1016/S1097-2765(01)00214-3
164. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 416:560-4. doi:10.1038/416560a
165. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 137:87-98. doi:10.1016/j.cell.2009.01.039
166. Marine JC, Berx G. Transforming growth factor-beta and mutant p53 conspire to induce metastasis by antagonizing p63: a (ternary) complex affair. Breast Cancer Res (2009) 11:304. doi:10.1186/bcr2337
167. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 2:1203-17. doi:10.18632/oncotarget.382
168. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer (2001) 1:68-76. doi:10.1038/35094077
169. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 8:282-8. doi:10.1038/nm0302-282
170. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 24:3484-91. doi:10.1038/sj.onc.1208419
171. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 15:376-88. doi:10.1016/j.ccr.2009.03.003
172. Saha MN, Chen Y, Chen MH, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer (2014) 110:2224-31. doi:10.1038/bjc.2014.164
173. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med (2011) 3:64rv61. doi:10.1126/scitranslmed.3001366
174. Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, et al. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (2008) 7:3440-7. doi:10.4161/cc.7.21.6995
175. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol (2008) 30:411-8
176. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther (2013) 12:2331-41. doi:10.1158/1535-7163.MCT-12-1166
177. Sobhani M, Abdi J, Manujendra SN, Chen C, Chang H. PRIMA-1Met induces apoptosis in Waldenstrom's Macroglobulinemia cells independent of p53. Cancer Biol Ther (2015) 16:799-806. doi:10.1080/15384047.2015.1026482
178. Piantino CB, Reis ST, Viana NI, Silva IA, Morais DR, Antunes AA, et al. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53. Clinics (2013) 68:297-303. doi:10.6061/clinics/2013(03)OA03
179. Shalom-Feuerstein R, Serror L, Aberdam E, Muller FJ, van Bokhoven H, Wiman KG, et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Proc Natl Acad Sci U S A (2013) 110:2152-6. doi:10.1073/pnas.1201753109
180. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 30:3633-9. doi:10.1200/JCO.2011.40.7783
181. Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, et al. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res (2015) 75:3842-52. doi:10.1158/0008-5472.CAN-13-1079
182. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest (2007) 117:1370-80. doi:10.1172/JCI30866
183. Maslon MM, Hupp TR. Drug discovery and mutant p53. Trends Cell Biol (2010) 20:542-55. doi:10.1016/j.tcb.2010.06.005
184. Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, et al. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res (2008) 68:6550-8. doi:10.1158/0008-5472.CAN-08-0137